NeoOPTIMIZE: An Open-Label, Phase II Trial to Assess the Efficacy of Adaptive Switching of FOLFIRINOX or Gemcitabine/Nab-Paclitaxel as a Neoadjuvant Strategy for Patients With Resectable and Borderline Resectable/Locally Advanced Unresectable Pancreatic Cancer
Latest Information Update: 16 Apr 2024
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary) ; Losartan (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Capecitabine
- Indications Adenocarcinoma; Ductal carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms NeoOPTIMIZE
- 11 Apr 2024 Planned primary completion date changed from 15 Apr 2024 to 15 Apr 2025.
- 12 Nov 2023 Treatments section is updated to add the procedures of Bio-specimen collection and diagnostic imaging.
- 12 Nov 2023 Planned primary completion date changed from 15 Jan 2024 to 15 Apr 2024.